Supply Chain Contingencies to Avoid Upheaval
Summary: Traditional efforts to optimize biomedical supply chains for quality and efficiencies of scale have been challenged by multiple, accelerating factors, including pandemic-related trade limitations, natural disasters, and policy proposals to limit U.S. government spending to domestically manufactured medicines. This session at the 2020 BIO Investor Forum features Catalent’s Karen Flynn, President of Biologics and Chief Commercial Officer, explaining the challenges and opportunities changing how biomedical supply chains must plan and innovate to continue to serve patients and build resilient future options.